Check-Cap Ltd. Ordinary Share
MBAI
NASDAQ Global Market1.58
USD
-0.09
- -
CIK
0001610590
ISIN
IL0011336851
CUSIP
001133685
Return %
Stock
S&P500
1Y
17.91
26.53
3Y
17.91
76.60
5Y
17.91
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Lontini
- Full Time Employees
- 85
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 29 Abba Hushi Ave. Isfiya Israel 3009000
- IPO Date
- Mar 4, 2015
- CIK
- 0001610590
- Website
- check-cap.com
- Similar Companies
- Business
- Check-Cap Ltd. (NASDAQ:MBAI) develops and commercializes the C-Scan system, a proprietary capsule-based colorectal cancer screening technology that utilizes ultra-low dose X-rays, an integrated positioning and control system, and software to generate 3D maps of the colon's inner lining for detecting precancerous polyps and structural abnormalities without bowel preparation; the system targets average-risk individuals seeking non-invasive, preparation-free alternatives to traditional colonoscopy to improve screening adherence. Primary products and services encompass the C-Scan disposable capsules, associated hardware for capsule control and recording, and proprietary image analysis software; the technology received CE Mark approval for Europe in 2015 and remains an investigational device in the United States. The company operates in the medical diagnostics industry, serving healthcare providers and patients focused on preventive colorectal cancer screening, with global ambitions centered in Europe, Israel, and the U.S. market pending further regulatory approvals. Founded in 2004 and headquartered at 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, Israel, Check-Cap maintains clinical-stage operations with approximately 85 employees. In a transformative strategic shift, Check-Cap entered into a definitive merger agreement on September 12, 2025, with MBody AI Corp. and its wholly owned subsidiary CC Merger Sub Inc., under which MBody AI will survive as a wholly owned subsidiary of Check-Cap to pivot toward embodied AI-driven automation platforms like the MBody AI Orchestrator for sectors including hospitality, logistics, healthcare, and warehousing; Check-Cap shareholders approved the merger on November 14, 2025, with over 98% support, alongside proposals for a reverse share split (1-for-2 to 1-for-100), director elections, and a name change to MBody AI Ltd. or similar, expecting closure in subsequent weeks subject to customary conditions. This alliance preserves the original exchange ratio despite MBody AI's surged pipeline, multi-year multi-million-dollar contracts with global brands, and heightened institutional interest exceeding hundreds of millions, positioning the combined entity for AI robotics expansion amid projections of trillions in market opportunity by 2030-2050.
Check-Cap (NASDAQ:MBAI) versus Bioventus (NASDAQ:BVS) Financial Survey
Reviewing TransEnterix (OTCMKTS:TRXDW) and Check-Cap (NASDAQ:MBAI)
Check-Cap (NASDAQ:MBAI) and Nanovibronix (NASDAQ:FEED) Head to Head Analysis
Critical Contrast: Carlsmed (NASDAQ:CARL) vs. Check-Cap (NASDAQ:MBAI)
Financial Analysis: Check-Cap (NASDAQ:MBAI) & Longevity Health (NASDAQ:XAGE)
MBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close
Head to Head Survey: Carlsmed (NASDAQ:CARL) & Check-Cap (NASDAQ:MBAI)
MBody AI to Begin Trading Under New NASDAQ Ticker Symbol "MBAI" $MBAI